GlassScriptPhysician profile
Kory Lord
NPI 1588303424
$4,971.15
in general payments reported to CMS, 2019-2025
24 companies · $3,331 in 2025
The $3,331 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.77 · 2023: $110 · 2024: $1,511 · 2025: $3,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,754 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,754.36 |
| Education | $197.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $831.25 | 2024-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $575.18 | 2024-2025 | Dupixent, Libtayo |
| Abbvie INC. | $528.40 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $364.27 | 2024-2025 | |
| Amgen INC. | $329.58 | 2024-2025 | Otezla, Otezla |
| Lilly USA, LLC | $312.86 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $293.02 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $219.82 | 2024-2025 | |
| Pfizer INC. | $199.27 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $191.97 | 2024-2025 | Zoryve |
| Organon LLC | $191.34 | 2024-2025 | Hadlima, Vtama |
| Leo Pharma INC. | $177.83 | 2024-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $141.30 | 2024-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $113.39 | 2025 | Sotyktu |
| Ucb, INC. | $107.09 | 2025 | Bimzelx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $101.46 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Dermavant Sciences, INC. | $87.30 | 2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Almirall LLC | $24.72 | 2024 | Klisyri |
| Kyowa Kirin, INC. | $24.68 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.91 | 2024 | Jublia |
| Exact Sciences Corporation | $22.23 | 2023 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $15.73 | 2025 | Tremfya |
| Astellas Pharma US INC | $15.56 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kory Lord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.